When patients are given the choice between a take-home test kit or undergoing a colonoscopy, more patients voluntarily undergo screenings, according to a May 22 press release from Penn Medicine.
The study looked at 738 patients aged 50-74 at a community health center in Pottstown, Pa., where about half of the patients are receiving Medicaid. The baseline colorectal cancer screening rate before the trial was about 22%, much lower than the national average of 72%.
“Offering the choice of colonoscopy or take-home kits seem to have the advantage of maximizing the rates of colonoscopy—the most effective screening tool—while not overloading individuals with too much of a choice, which could have lowered overall participation,” Shivan Mehta, MD, Penn Medicine’s associate chief innovation officer, associate professor of gastroenterology and the study’s lead author, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.